You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence ...

How Jeffrey Epstein's friend came back to biotech, probes into the FDA's drug rejections, and other biotech news ...

The first patient I met as a medical student was a middle-aged delivery man and a former track athlete. He was recovering from his second amputation due to uncontrolled type 2 diabetes. When he told ...

The Trump administration push for lower U.S. drug prices helped Astellas secure higher pricing for its new eye medicine in Japan ...

Boris Nikolic’s career looked to be in tatters after his friendship with Jeffrey Epstein came to light in 2019. But he has quietly made a comeback, with some help from a top biotech VC.

AI agents to perform health care work are everywhere at HIMSS 2026. Experts want to know more about their validation.

A new nonprofit called Radial is launching with at least $500 million to modernize the scientific process for the AI era.

Epstein's "great friend" returns to biotech, sex differences in suicide, and other health news from Morning Rounds ...

The FDA approves leucovorin for a rare brain disorder while retreating from top officials’ earlier insistence that it could ...

The FDA is cutting back on public advisory committee meetings, even as the public and other stakeholders seek more ...

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney ...

Removing race from the eGFR had a big impact, resulting in 5.3 more kidney transplants per 1000 Black candidates.